These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 1982193)
21. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Baker DE Rev Gastroenterol Disord; 2002; 2(1):20-33. PubMed ID: 12122976 [TBL] [Abstract][Full Text] [Related]
22. 'Generally safe' NSAIDs? Rosen Z Am Fam Physician; 2001 Feb; 63(4):637. PubMed ID: 11237080 [No Abstract] [Full Text] [Related]
23. [Clinical strategy to prevent the gastrointestinal adverse effects of nonsteroidal anti-inflammatory agents]. Lanas A; Martin-Mola E; Ponce J; Navarro F; Piqué JM; Blanco FJ Gastroenterol Hepatol; 2003 Oct; 26(8):485-502. PubMed ID: 14534022 [No Abstract] [Full Text] [Related]
24. [NSAIDs or coxibs: benefits and gastrointestinal vs. cardiovascular effects]. Ballesteros Amozurrutia MA Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():22-5. PubMed ID: 17037763 [No Abstract] [Full Text] [Related]
25. [Adverse effects of non-steroidal anti-inflammatory drugs. II. Adverse effects of heterocyclic enols]. Janiec W; Pietryka B; Pytlik M; Leszczyńska J Wiad Lek; 1985 Dec; 38(24):1745-50. PubMed ID: 3834676 [No Abstract] [Full Text] [Related]
26. Use of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 (COX-2) inhibitors: indications and complications. Pascucci RA J Am Osteopath Assoc; 2002 Sep; 102(9):487-9. PubMed ID: 12361181 [TBL] [Abstract][Full Text] [Related]
27. Effect of non-steroidal anti-inflammatory agents on the upper gastro-intestinal tract: gastroscopic findings in Nigerians. Atoba MA; Olubuyide IO Cent Afr J Med; 1989 Jul; 35(7):427-30. PubMed ID: 2582486 [TBL] [Abstract][Full Text] [Related]
29. [Endoscopic capsule: position paper of the Catalan Society of Gastroenterology]. González Suárez B; Dedeu Cuscó JM; Galter Copa S; Mata Bilbao A Gastroenterol Hepatol; 2011 Oct; 34(8):573-83. PubMed ID: 21855177 [No Abstract] [Full Text] [Related]
30. Gastro-intestinal lesions induced by non-steroidal anti-inflammatory drugs. Albu R; Dragomir P; Voiosu R Rom J Intern Med; 1998; 36(3-4):145-59. PubMed ID: 10822511 [TBL] [Abstract][Full Text] [Related]
32. Gastrointestinal outcomes: evidence for risk reduction in patients using coxibs. Scheiman JM Am J Manag Care; 2002 Nov; 8(17 Suppl):S518-28. PubMed ID: 12458821 [TBL] [Abstract][Full Text] [Related]
33. [Adverse effects of nonsteroidal antirheumatic agents on the digestive tract]. Lukás M; Chalupná P; Adamec S; Bortlík M; Novotný A Sb Lek; 2002; 103(2):265-72. PubMed ID: 12688151 [TBL] [Abstract][Full Text] [Related]
34. Gastrointestinal side effects of the nonsteroidal anti-inflammatory drugs. Taragin MI; Carson JL; Strom BL Dig Dis; 1990; 8(5):269-80. PubMed ID: 2257693 [No Abstract] [Full Text] [Related]
35. [The therapeutic action of mineral waters in diseases of the digestive organs]. Shvarts VIa; Frolkov VK Vopr Kurortol Fizioter Lech Fiz Kult; 1990; (1):20-4. PubMed ID: 2336822 [TBL] [Abstract][Full Text] [Related]
36. Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: mechanisms and prevention. Rich M; Scheiman JM Semin Arthritis Rheum; 2000 Dec; 30(3):167-79. PubMed ID: 11124281 [TBL] [Abstract][Full Text] [Related]